Tuesday, September 30, 2008
Sunday, September 28, 2008
"Leaving on a Jet Plane" John Deutschendorf, but I first heard it by Peter, Paul and Mary
"Happiness runs in a circular motion" Donovan
Friday, September 26, 2008
"We're so sorry, Uncle Albert" Paul McCartney
Thursday, September 25, 2008
"Lettuce be lovers, We'll marry our fortunes together" With apologies to Simon and Garfunkel
"Well, I ain't superstitious" Willie Dixon
Wednesday, September 24, 2008
"It wouldn't be make-believe if you believe in me" Arlen and Harburg
Tuesday, September 23, 2008
" It is never too late to start all over again" Steppenwolf
We'd get by
If only you believe in miracles, baby
So would I
Monday, September 22, 2008
"Please Please, Mr. Postman Wait and see Is there a letter in your bag for me" Garrett, Holland, Gorman, Dobbins, Bateman Performed by the Beatles
Sunday, September 21, 2008
"Where are You? Adamson and McNugh (sung by Old Blue Eyes)
"Don't come around here no more" Tom Petty and the Heartbreakers
You darken my door
Whatever you're looking for
Hey, don't come around here no more
Remember also the fable of the doubling of the rice grain. The Chinese emperor was so happy with the invention of the game of chess, he asked the inventor what gift he would like. He replied only that 1 grain of rice be placed on the first square of the chess board, 2 on the next and then 4, 8 16 constantly doubling until the 64th square was reached. The ruler was insulted by the meager demand, insisting that such a request did not befit an emperor. The inventor persisted asking only for the emperor's promise to comply or the throne and all it's wealth and power were his. Agreed. You know the rest of the story: 2 to the 64th power is approximately 2 followed by 19 zeros, more than the world's production of rice.
I tell this apocryphal tale to emphasize that it all starts with just one bad cell or one grain of rice, but given enough time and enough doubling, the numbers can become scary. Add to this the survival of the fittest. The few clonal cells not destroyed in the battle are the most robust, the most resistant, and are very pissed off. And their competition for space and resources has been eliminated.
I don't say this too dishearten, just to prepare. This does not mean there is no escape. Many of us will die years down the line of other cause before CLL reoccurs. For others our more healthy immune system rebuilt during a long remission or with a transplant will be constantly finding and destroying any clonal activity before it is even apparent. The price of freedom is indeed eternal vigilance.
That's my take.
Saturday, September 20, 2008
Friday, September 19, 2008
"I've got x-ray eyes" Kiss
Wednesday, September 17, 2008
'Life's a Beach"
Monday, September 15, 2008
"It's still the same old story A fight for love and glory A case of do or die. " Herman Hupfeld
"Anticipation, anticipation Is makin' me late Is keepin' me waitin'" Carly Simon
Friday, September 12, 2008
"Cause it's the little things, oh, that mean a lot. It's what you are, not what you got" Sonny and Cher
Monday, September 8, 2008
"Celebrate good times, come on! (Let's celebrate)" Cool and The Gang
I just returned from the doctor and I am bursting with the good news: No leukemia in the bone marrow. If this is not an outright cure, it is at least a deep remission, (MRD negative by 4 color flow cytometry for the CLL savvy) a necessary and critical step in the right direction of leaving CLL disappearing in the rear view mirror. Like my friend, Robert flooring his tricked out Porsche Carrera and saying goodbye to my beemer like it's standing still. Or that my nice sport sedan is moving in reverse. This is a true high five moment. CT scans and engraftment studies are still pending. I will write soon about what this could mean and how it fits into the whole picture, but nothing, nothing at all can take away the joy of this moment.
I am so happy.
Pardon all the adolescent car imagery. We are still looking for wheels for Ben ( email him at vincentmeloy@aol.com if you can help, please).
Sunday, September 7, 2008
" I won't back down" Tom Petty and the Heartbreakers
Friday, September 5, 2008
"Get on down to the main attraction. With a little less talk and a lot more action." Toby Keith
Thursday, September 4, 2008
"I want to tell you. I feel hung up and I don't know why" The Beatles
"To be or not to be isn't the question. The question is how to prolong being."
Here's a letter I just wrote to a friend, my favorite author. It provides an overview of my story June through September.
I had the bone marrow biopsy today. All I can say is OUCH! Not that bad really. Dr. Forman says the main thing he is looking for for any CLL that might be hiding in deep in the bones, not the percentage engraftment. On the way home, Patty and I walked through a surprisingly wild and woodsy trail with dappled and turtled creeks and lakes, all of this, believe it or not, in Long Beach. It is good to walk after the biopsy. Doesn't let those needled muscles and bone stiffen up. Truth be told, it is good to walk any time. Especially in nature. Then take a long nap.
Sept. 3, 2008
Dear ----,
Much has happened since I last wrote in June about my then planned bone marrow transplant. It happened, as scheduled, July 1.
I have hesitated to contact you until I had some clarity on my progress in morphing to a chimera, on the road to a cure, but that might be a long wait.
I received my IV shot of redemption, my new immune system, in the form of stem cells packed in ice, then quickly flown by courier after being donated by a 22-year-old Israeli Yeshiva student who was a perfect 12/12 match, my biological doppelganger. My hospital course was unusually easy, and to everyone’s’ surprise and delight, I was shipped home only 3 weeks later.
I am now bald and on a most restrictive low bacteria diet. I must wear a special mask when I leave the house, but I am home with my wife and, until last week, my kids. The pets and plants are still off limits.
Not a single major complication. I just tire easily. And I fight the ennui from being stuck at home for months to come.
I am planning to write. Non-fiction. Now that’s work that makes a transplant look like a walk in the park!
The big issue is that I have been excessively slow to engraft, or have my donor cells dominate my blood and bone marrow. I am still what is medically called “ mixed chimerism”, part donor, part old me.
T cells are the generals of the immune system that give the marching orders to the other white blood cells, the killers and the helpers of the immune system. Mine are a healthy 2/3 from my young student rabbi donor. Trouble is that the troops have been most stubborn, refusing to fall in line and my peripheral blood is only 28% donor, down from 32% last month.
This might be perfect and I may be walking a gentle and slow Buddha-like middle path that is both keeping me from the dreaded graft versus host complications and at the same time providing enough of the new immune system (my old one was corrupted by the cancer) to search out and destroy my leukemia. The best of both worlds. The holy grail of the transplant world.
But it also might mean that I am rejecting the graft and may need to start the whole process all over. That is not only trying, but risky. Tomorrow I am having a bone marrow biopsy, which might sort this out, or not. I pushed my doctor not to wait a month to literally drill for more information. The biopsy will at best relieve my false worries 3 weeks sooner or at worst, allow a prompt response to a most difficult situation, before it is a fait accompli.
I’d be lying if I said it was easy to stay both vigilant and upbeat at all time. Meditating helps. Love is the engine of change and survival, but it’s still tough.
The tests will not only determine when I can toss my mask, eat a salad (or vice versa) or go to a concert or get on a plane. They might reveal my future.
Then again, I was never promised clarity. I was only promised risks.
I wish I could have laid out for you a painted scene with wider vistas and deeper perspectives, but there will be time for that in the future. For now, my friend, I must entangle you in the details of the process.
A quick Koffman family update: Patty is playing drums in our living room; Rachael is designing low cost housing in San Francisco; Nick is hoping to circle the globe developing plans to recycle obsolete American military bases; Heather has just started her Manhattan law practice; Ben is filming a JBL/Caltech movie about radio telescopy and another about the punk scene in Santa Ana, and Will is studying art in Florence, Italy.
Be well. Stay in touch. Drop by if you venture to SoCal.
Brian Koffman
DR Castro's Study as UCSD
These looks pretty exciting. It is trying to get the immune system to wake up and attack the cancer. It you are at all interested. contact Dr Castro and his team at UCSD to get all the details.
Below if the informed consent
060201
Intanodal ISF35
Rev.6.22.07
Page 1 of 10
University of California, San Diego
Consent to Act as a Research Subject
A PHASE 1, OPEN LABEL, DOSE-ESCALATION, PHARMACODYNAMIC STUDY OF
INTRANODAL INJECTION OF ADENOVIRUS-CD154 (Ad-ISF35) IN PATIENTS
WITH CHRONIC LYMPHOCYITC LEUKEMIA / SMALL LYMPHOCYTIC
LYMPHOMA
Januario E. Castro, MD and his associates are conducting a research study that uses an experimental agent called Adenovirus-ISF35 or Ad-ISF35. Ad-ISF35 is a cold virus that has been changed in the laboratory so that it is not likely to reproduce or cause an infection once it is in your body. Ad-ISF35 will be injected into your lymph nodes and your response to this injection will be monitored. In this case, the adenovirus is used to add a copy of ISF35 to your leukemia cells. The injection of Ad-ISF35 is considered ‘investigational’, that is, not approved by the FDA (Food and Drug Administration).
You are being asked to take part in this study because you have chronic lymphocytic leukemia (CLL) or small cell lymphocytic leukemia (SLL) and have either been treated unsuccessfully by other standard means or have chosen not to receive chemotherapy.
This study is being done at UCSD; approximately 23 subjects will be enrolled.
Study Purpose
The goal of this clinical research study is to evaluate the safety and side effects, as well as to evaluate any potential clinical and biologic response to ISF35 as used in this study.
Study Procedures
If you agree to be in this study, the following will happen to you:
Screening
After you have plenty of time for all of your questions to be answered about this experimental procedure and you sign this informed consent form, several tests will be done. These tests help the doctor decide if you are eligible to take part in the study:
- you will be asked to give your complete medical history including past treatments for CLL or SLL, current or past medical conditions and surgeries, and what medications you take
- you will have a physical examination.
- 40 ml (2 and 1/2 tablespoons) of blood will be drawn for several blood tests including ‘routine safety’ labs such as a CBC (complete blood count that checks the number of various blood cells), and blood chemistries that check the function of you liver and kidneys. In additional blood is drawn for ‘research’ purposes; see the ‘Optional
Procedures’ section below.
- chest x-ray
- electrocardiogram (EKG ) - a test that measures the electrical activity of your heart by placing sticky pads on your chest).
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
10 pages
060201
Intanodal ISF35
Rev.6.22.07
Page 2 of 10
- 10 mL (2 teaspoons) of blood taken for tests to determine if you have been exposed to,
or have an active infection with, certain viruses. These viruses include Hepatitis B and
C Virus (HBV & HCV respectively), viruses which cause liver disease in their active
form, and
- Human Immunodeficiency Virus (HIV), the virus that causes acquired immune
deficiency (AIDS). To have your HIV test performed, you will be asked to sign an
additional consent form required by the UCSD Medical Center. If you have antibodies
(blood proteins formed by the immune system in response to foreign material) to HIV
in your blood, you will not be eligible for this study. A positive antibody test to
certain viruses is expected for some individuals and does not necessarily mean that you
have an active infection. Dr. Castro and/or his associates, will discuss your lab results
with you and determine if you have an active viral infection requiring further treatment
and exclusion from this study, or if you do not have an active infection and are still
eligible for this study.
- Women who are able to have children must have a negative pregnancy test.
Administration of ISF35
If you are found to be eligible for this study, the following procedures and test will be done:
- a marrow biopsy (this is standard procedure that allows physicians to evaluate the
extent of leukemia / lymphoma contained in the marrow). Another marrow biopsy
may be required at the end of the follow up period (day 84 after injection of Ad-
ISF35).
- You will be admitted for this study to the General Clinical Research Center (GCRC)
located in the main hospital of UCSD. Ad-ISF35 will be injected directly into one
selected lymph node located in your either in your neck, above the clavicle (collar
bone), axilla (armpit area) or groin area. The Interventional Radiologist will monitor
the needle placement and directly perform the injection of the agent. The ultrasound
imaging will continue during the injection to watch for any intravasation (leakage).
- The lymph node to be injected will be selected depending upon its size and how easy
is to access, evaluate and inject that particular lymph node. This procedure will be
performed under local anesthesia and using an ultrasound machine to locate the
lymph node and determine that the virus is injected into the lymph node without
leaks.
- A total of about 90 ml (6 tablespoons) of blood will be taken for routine blood tests
and research studies at the time of admission.
- Vitals signs will be recorded several times during your hospitalization.
- You will remain hospitalized for observation for 24 hours. Prior to discharge you will
have another physical exam and another blood test (30 mL about 2 tablespoons)
Monitoring for Safety and Response
You will be asked to return to UCSD clinic –
48 hours after injection of Ad-ISF35, you will undergo:
- a complete physical examination and
- about 30 ml (2 tablespoons) of blood will be taken for routine blood tests and
research.
Day 7 after injection of Ad-ISF35, you will have:
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 3 of 10
- another physical exam,
- blood collection of about 30ml (2 tablespoons) and
Day 14, day 21, day 28, day 56, day 84, you will return to the UCSD clinic and undergo:
- a brief physical examination and
- about 30 ml (2 tablespoons) of blood will be taken for routine blood tests and
research.
Follow-up
Every 3 months, for 12 months after the injection of Ad-ISF35, you will be asked to return to
clinic and the following procedures will be done:
- Physical examination including vital signs, lymph node, spleen and liver
measurements, performance status, adverse event assessment, concurrent
medications, and recording of transfusion of blood products; AND
- CBC with differential, platelet count, complete chemistry panel with uric acid, LDH
and Beta-2 microglobulin
At the 12 month post visit only you will also have blood drawn for:
- Quantitative immunoglobulin levels (IgG, IgA, IgM) AND absolute T cell count
including CD3+, CD4+, and CD8+ populations.
Optional Procedures - You do not have to agree to take part in the optional procedures in order
to receive participate in this study.
1. Optional Blood Draws for Correlative Studies - If you agree, you will have about 2 teaspoons
of blood drawn before the injection of ISF35, 48 hours after the injection and on study Days 7,
14, 21, 28 56, and 84 to evaluate whether the ISF35 is stimulating your immune system, to
evaluate how your immune system is responding, and to see the effects of the ISF35-treated cells
on your leukemia cells.
If you agree, leftover leukemia cells collected during this study will be stored in a tissue bank.
These cells may be used in the studies of your immune system conducted by Dr. Castro and his
colleagues at University of California, San Diego (UCSD). The collected leukemia cells, and
their genetic information (DNA), may have significant therapeutic or commercial value.
You agree to the Optional Blood Draws
Yes No Initials/Date: ________________________
2. Optional Quality of Life Questionnaire (QOL) - If you agree, you will complete a ‘QOL’
questionnaire to evaluate how the ISF35 affects your quality of life (QOL); this will be done
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 4 of 10
before you begin to receive ISF35, before your infusions, and 2 weeks and 2 months after your
infusion. Each of these questionnaires should take between 15 – 20 minutes to complete.
You agree to the Optional Quality of Life Questionnaire
Yes No Initials/Date: ________________________
Duration of Participation
Overall, your time on this study will be about 2 years. During this period of follow-up, you may
return to be seen by your primary care doctor. Your doctor will be asked to provide information
on any changes in your health and medical treatment from the end of the study until 2 years from
your infusion. If your disease worsens during the follow-up period, you may come off the study
to begin standard treatment if needed.
Study Risks
Participation in this study may involve some added risks or discomforts. These include:
1. ISF35
ISF35 may cause flu-like symptoms such as fever, muscle and joint pain and stiffness, weakness,
and/or nausea. It may cause headache, diarrhea, low blood pressure, vomiting, difficulty
breathing, and/or pain in various body areas. It may cause significant loss of body water,
difficulty sleeping, loose stools, night sweats, and/or increased sweating. It may cause swelling,
bloating, collection of abdominal fluid, constipation, skin rash, upset stomach, frequent
urination, and/or a cough that brings up secretions. It may cause running nose, sinus infection or
inflammation, and/or weakness. Your doctor may give you acetaminophen (Tylenol) for
relieving flu-like symptoms.
ISF35 may cause a decrease in blood platelets, red blood, or white blood cells. If temporary
reduction of platelets occurs, this may cause increased susceptibility to bruising and to bleeding;
a decrease in red cells may cause you to become anemic and fatigued; a reduction of your white
cells may cause increased susceptibility to infection; any of these could be life threatening and
you may need a blood transfusion.
ISF35 may cause increased liver enzymes, which may mean liver damage. It may cause
increased blood urea (a waste product made by the liver and excreted by the kidney) and/or
decreased blood albumin (a protein found in blood that helps move water throughout the body),
which may result in water gain in certain areas of the body. ISF35 may cause increased blood
bilirubin (a byproduct of the breakdown of red blood cells), increased blood creatinine (a blood
waste product), and/or high blood sugar.
The frequent blood tests taken are meant to monitor for any changes in either blood cell counts
or blood chemistries.
CD154 protein
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 5 of 10
Your immune system may form antibodies (blood proteins formed by the immune system in
response to foreign material) against the human or the mouse CD154 protein, which is part of
ISF35. While antibody formation against the mouse CD154 (present in the ISF35 virus) was
observed in another study, this was not associated with any known safety risks. However, it is
not yet known whether the formation of these antibodies reduces the effectiveness of this new
investigational procedure. Antibodies against human CD154 have not been detected. The
formation of such antibodies may indicate a development of an immune reaction directed against
cells other than the leukemia / lymphoma cells (risk of autoimmune disease). The purpose of
giving you a lymph node injection with ISF35 is to altered leukemia / lymphoma cells contained
in the lymph node and stimulate your immune system to recognize and to attack your leukemia /
lymphoma cells. This will be a positive effect if the body recognizes the leukemia / lymphoma
cells and works to destroy them. However, it is possible that the immune system also may attack
other cells, causing unwanted autoimmunity, a condition in which the body attacks its own
tissues.
In this study, blood tests are done at regular intervals to detect the formation of antibodies.
Ad-ISF35 is intended to activate the immune system against the leukemia cells. There are other
methods being developed to activate the immune system that are also being studied in humans
with cancer and other diseases. Activating the immune system could bring about an immune
response against the cancer cells but could also cause unwanted side effects and toxicities.
One method of activating the immune system, which is not related to this study, uses antibodies
to activate the immune system. One study used antibodies that attach to the surface of immune
cells (T cells). When these antibodies were given to normal volunteers in a study conducted in
Europe (TeGenero TGN1412), the treated patients had unexpected and serious toxic effects.
These effects included severe headaches, muscle aches, nausea, diarrhea, redness of the skin and
low blood pressure, fluid involving the lungs, kidney damage and blood clotting problems. Two
patients had damage to the heart and lungs that required prolonged treatment in the intensive care
unit and hospitalization. Despite of the severity of these responses, all the treated subjects
survived and were able to leave the hospital. However, some of the patients still have medical
problems that have yet to resolve. Although this study is unrelated to the current study and uses
entirely different technology, it is an example of a strong immune response that can have very
serious consequences.
Adenovirus Vector
Adenoviruses are a common cause of colds. The vector might cause shortness of breath and/or
allergic reactions, including hives, skin rash, difficulty breathing, and/or fever. They can cause
lung infections that generally are not serious and go away on their own. However, on rare
occasions, adenoviruses can cause cough, bronchitis, and pneumonia that can be serious and
conceivably life threatening. Also, the adenovirus can infect the liver. This may cause hepatitis
(inflammation of the liver), jaundice (yellowing of the skin or whites of eyes), or liver failure,
and thus could be life-threatening. The injection ofAd-ISF35 will be local and no major leak
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 6 of 10
into the blood system is expected. However, this is a safety concern as the adenovirus could
infect other organs of the body, leading to unknown problems and potential life-threatening
reactions which could include damage of vital organs such as the liver and spleen as well as
activation of the immune system against your own cell and tissues, a process that is called
autoimmunity.. At another institution, in a gene therapy trial that was unrelated to this trial, a
subject was injected with a large amount of adenovirus and the subject subsequently died. In this
clinical trial, the virus will be delivered locally into a lymph node, and all efforts are made to
reduce the amount of virus leak that potentially can enter the blood. Also, the adenovirus used in
this protocol is ‘crippled’ and is not able to reproduce itself inside your body because the
essential parts for reproduction were removed.
There is a small chance that there may be normal infective virus in the preparation that you will
receive. There is also a small chance that this virus or the virus vector may be excreted for a
short period of time in your body fluids. Close friends and family members should avoid contact
with your body fluids for a period of two (2) weeks after the administration of the virus vector.
2. Lymph node injection with Ad-ISF35
The procedure will be performed under local anesthesia using lidocaine (local anesthesia
medication). However, Ad-ISF35 injection can cause local pain and discomfort during the
injection and during the following days after the injection is performed. The local reactions are
unknown but could include redness of the skin, pain, infection and potentially damage or loss of
the local skin and tissue where the injection was performed. The ultrasound procedure that will
be used for localization and injection of the lymph node is painless and does not have associated
side effects.
There is a small risk that you may experience low blood pressure and/or temporary shifts
(increases and decreases) in the mineral content of your blood. Slight abnormalities in the
mineral content of your blood could result in muscle twitching or a tingling sensation,
particularly around the mouth. More severe abnormalities in the mineral content of your blood
could result in tetany (severe muscle contractions) or abnormal electrical activity in your heart,
either of which could be fatal. Because of this, you will be monitored closely for changes in
your blood pressure and symptoms that may indicate a change in the mineral content of your
blood.
3. Other Medications
Antibiotics are used to prevent infection during the preparation of your leukemia cells in the
laboratory. You may experience an allergic reaction against some of the antibiotics.
Medications that can be used to manage an allergic reaction include antihistamines, steroids,
oxygen, epinephrine (adrenaline), and medications used to maintain blood pressure. For life-
threatening allergic reactions, it may be necessary to place a breathing tube in your airway. A
breathing machine (mechanical ventilator) could then be used to assist with your breathing until
you have recovered.
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 7 of 10
5. Radiation Risk - As a result of participating in this study, you will be exposed to a small
amount of radiation (approximately 0.024 cGy). This amount is less than you would
receive from a year of natural exposure, approximately 0.16 cGy. This dose should not be
harmful. If you are especially concerned with radiation exposure or you have had a lot of x-rays
already, you should discuss this with your doctor.
6. Blood Draws - the risk of having blood drawn through a vein includes pain, bruising,
swelling, irritation at the site of the blood draw, and rarely an infection could develop. You may
feel dizzy, lightheaded or faint when blood is taken; if you are prone to fainting, please inform
your doctor prior to having blood drawn.
7. Risks of Hepatitis Testing - Testing for hepatitis viruses may result in a diagnosis of
infection with these viruses. You will be informed of the results of these tests; if you do not wish
to know the results, you should refuse to participate in this study. In the event that you are
diagnosed with hepatitis, you may be referred to a doctor who specializes in these illnesses. The
diagnosis of hepatitis may result in earlier treatment and/or prevention of many complications
from the illnesses. Efforts will be made to keep your personal information confidential.
Awareness of a diagnosis of these illnesses may have serious person or social consequences.
Some of these consequences include possible difficulty obtaining health insurance or
employment, and difficulty traveling to some foreign countries.
8. Bone Marrow Biopsy – For a marrow biopsy and aspirate, you will be given a numbing
medicine and a special needle will be put into the center of your (hip) bone. The marrow aspirate
will be drawn into a syringe. A marrow biopsy is similar to a marrow aspiration, except a
sample of bone is removed through the needle. It is very painful when marrow is removed but
pain will last only last 15 – 30 seconds. However, the area may be sore for a day or two. It is
very rare, but you may have an allergic reaction to the numbing medicine; this reaction may
include swelling in the throat, difficulty breathing, changes in heart rate or blood pressure, rashes
or even death in rare cases. A large amount of bleeding or an infection are possible but are rare.
9. Blood Test - DNA/Gene Profiling - Your white blood cells and the DNA that they contain
may be used in additional research to be conducted by the University of California. Your blood
and its derivatives (DNA, which is the genetic material insides your cells), may have significant
therapeutic or commercial value. You consent to such uses.
Your samples will be kept indefinitely. There will be no direct benefit to you from these studies
since you will not be provided with any results or information regarding your DNA gene profiling
tests. Dr. Castro and his colleagues, however, may learn more about CLL.
Instances are known in which a subject in research has been required to furnish genetic
information as a precondition in applying for health insurance and/or a job. Participation in this
study does not mean that you have had genetic testing. Genetic testing means having a test
performed and the results provided to you and your doctor. If you are interested in having
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 8 of 10
genetic testing performed you should consult your doctor, as some commercial tests are
available. Further, should this information be accidentally divulged to the wrong source you or
your family might be discriminated against in obtaining life or health insurance, employment or
ability to adopt children.
10. Reproductive Risks
If you are a female and capable of child-bearing, a sample of urine or blood will be collected
before the study is begun in order to be as sure as possible that you are not pregnant. Your
participation requires that you use a birth control method, such as abstinence, diaphragm,
condom or intrauterine device to prevent pregnancy during the study, as the IDF35 being tested
may cause harm to an unborn child. If you miss a period or think you might be pregnant, you
will notify the doctor. You may have to withdraw from the study
All participants (including men who have not been surgically sterilized) are required to use an
effective birth control method of their choice including barrier methods (condoms, diaphragm),
oral, injectable, implant birth control, or abstinence to ensure that pregnancy does not occur
while being treated on this study and for at least two (2) weeks after the last virus vector
treatment.
11. Transfusions
The likelihood of requiring a blood transfusion is not expected to increase due to your
participation in this study. However, patients with CLL or SLL may require transfusions because
of anemia or low platelet counts. If a blood transfusion is required, potential risks of transfusion
due to anemia and/or low platelet count may include: discomfort and anxiety, breathing
difficulty, facial flushing, severe pain in the neck, the chest and especially the low back area.
Evidence of shock may appear, including a rapid feeble pulse, cold clammy skin, shortness of
breath, a drop in blood pressure, nausea and vomiting. Onset of these symptoms usually occurs
during or immediately after transfusion. Other side effects include: fever, allergic reaction, and
too much build up of fluid, which may cause congestive heart failure, chills and death.
Infectious agents such as HIV and Hepatitis B and C may be transmitted by transfusions. The
University of California San Diego Blood center routinely screens for these infectious agents.
12. Unknown Risks
Since this is an experimental agent there may be some unknown risks that are currently
unforeseeable. You will be informed of any significant new findings.
Study Benefits
The main purpose of this protocol is to assess the safety of the experimental agent. In the
preceding study, subjects who received a single infusion of genetically altered leukemia cells,
had reduced lymph node swelling, a decrease in their leukemia cell counts, and an increase in the
number of some specialized non-leukemic white blood cells (T-lymphocytes). However, it is
unknown whether a single lymph node injection of ISF35 will be beneficial to you.
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 9 of 10
Alternatives to Participation in this Study
At present, there is no cure for CLL. Treatments for relief of symptoms are available if
treatment is indicated. Patients who have received treatment for advance stage CLL may be
treated with other types of chemotherapy, radiation therapy, stem cell transplantation (if
eligible), or may receive no specific treatment other than for symptoms such as blood product
transfusions or pain medications. Those patients with untreated advance stage CLL may be
treated with chemotherapy, radiation therapy, stem cell transplantation (if eligible), or may
receive no specific treatment other than for symptoms such as blood product transfusions or pain
medications. Also, none of the mentioned standard treatments for CLL has been shown to
prolong survival in treated patients, but they may improve some symptoms associated with this
disease. The study doctor will discuss these options with you.
Voluntary participation
Taking part in this research study is your decision. You may decide to stop at any time without
jeopardy to the medical care you will receive at this institution or loss of benefits to which you
are entitled. You should tell the study doctor if you decide to stop and you will be advised
whether any additional tests may need to be done for your safety.
Confidentiality
Dr. Castro, his research team, the UCSD Investigational Review Board, the U.S. FDA, and
governmental agencies in other countries where the study drug may be considered for approval,
will have access to confidential information that could be linked to your name. Research records
will be kept confidential to the extent allowed by law.
Compensation for Participation
There will be no payment made to you for participation in this study. ISF35 is investigational
(not approved by the FDA) and will be provided by Memgen LLC (a biotechnology company
located in San Diego, CA) at no cost to you. Memgen is not sponsoring this study, will not have
access to your medical records, and your privacy will be protected according to HIPAA
regulations.
Costs associated with the standard and customary care of your leukemia/lymphoma will be billed
to your insurance provider or third party payer. If your third party payer, or insurance provider
does not cover the routine medically prudent care for the treatment of your leukemia/lymphoma,
you may be responsible for the total amount of those charges. All research related costs, such as
research related laboratory tests, diagnostic tests, and the process involved in the production of
ISF35 for injection will be not be charged to you.
Compensation for Injury
If you are injured as a direct result of participation in this research, the University of California
will provide any medical care you need to treat those injuries. The University will not provide
any other form of compensation if you are injured. You may call the UCSD Human Subjects
office at (858) 455-5050 for more information about this or to report research-related problems.
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008
060201
Intanodal ISF35
Rev.6.22.07
Page 10 of 10
Withdrawal from Study
You may be withdrawn from the study if Dr. Castro believes that it is in your best medical
interest, or if you do not follow the instructions given you by the study personnel. You may also
decide that you no longer wish to continue in this study.
At the time of withdrawal, you will have a final physical examination, and blood will be taken
for routine safety labs.
Agreement to Participate
Dr. ________________ has explained this study to you and answered your questions. If you
have other questions or research-related problems, you may call Dr. Castro at (858) 822-6600.
After hours or on weekends, please call the page operator at (858) 657-7000 and ask to speak
with the oncologist on call.
You have received a copy of this consent document and a copy of the Experimental Subject's
Bill of Rights to keep.
You agree to participate.
___________________________ _________________________ _______________
Subject's signature Subjects Printed Name Date
____________________________ _______________
Witness Date
Approved
Initial Approval: 2/16/2006
Current Approval: 7/19/2007
Do not use after: 1/17/2008